MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10781552221142870

Медицинская библиотека · Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2022

Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma.

Kars Taha Ulutan, Yorgancı Zahit Furkan, Yaşkıran Osman, Tekinalp Atakan, Demircioğlu Sinan

Клинический случайСтатьяПеревод в очереди

Аннотация

INTRODUCTION

Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Rituximab may cause thrombocytopenia in the long term after administration. Rare cases of rituximab-induced acute thrombocytopenia have been reported in the literature.

CASE REPORT: A 51-year-old female patient who was newly diagnosed with splenic marginal zone lymphoma received rituximab as first-line therapy. Petechiae occurred in the lower extremities on the day following rituximab administration. The blood test showed a severe drop in the platelet count from 112,000/μL to 5000/μL. Blood peripheral smear evaluation confirmed severe thrombocytopenia.

MANAGEMENT AND OUTCOME: There was no change in hemoglobin or white blood cell levels. After the diagnosis of rituximab-induced acute thrombocytopenia, thrombocyte suspension was administered due to the risk of bleeding. Close clinical and laboratory observations were made. The platelet count began to rise gradually in the following period. Before the second week of rituximab administration, the platelet count was 122,000/μL. No complications developed after premedication and slow rituximab administration, and subsequent treatments were continued in the same way.

DISCUSSION: Rituximab has widespread use, especially in malignancies and autoimmune diseases. Like many monoclonal antibodies, rituximab has several side effects. Thrombocytopenia is a long-term side effect associated with rituximab, and rituximab-induced severe acute thrombocytopenia has been rarely reported. Therefore, it should be kept in mind that severe acute thrombocytopenia may develop after rituximab administration.

Для цитирования: Kars Taha Ulutan, Yorgancı Zahit Furkan, Yaşkıran Osman, Tekinalp Atakan, Demircioğlu Sinan. Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022. DOI: 10.1177/10781552221142870.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.